Literature DB >> 19092295

RAD52 polymorphisms contribute to the development of papillary thyroid cancer susceptibility in Middle Eastern population.

A K Siraj1, M Al-Rasheed, M Ibrahim, K Siddiqui, F Al-Dayel, O Al-Sanea, S Uddin, K Al-Kuraya.   

Abstract

Genetic polymorphisms of DNA repair genes seem to determine the DNA repair capacity. We hypothesized that polymorphisms of genes responsible for DNA repair may be associated with risk of thyroid cancer. To evaluate the role of genetic polymorphisms of DNA repair genes in thyroid cancer, we conducted a hospital-based case-control study in Saudi population. Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN. RAD52 GLN221GLU genotypes CG and variants carrying G allele showed statistical significance and very high risk of developing thyroid cancer compared to wild type [CG vs CC; p<0.001, odds ratio (OR)=15.57, 95% confidence interval (CI)=6.56-36.98, CG+GG vs CC; p<0.001, OR=17.58, 95% CI=7.44-41.58]. Similarly, RAD52 2259 genotypes CT and variant allele T showed a significant difference in terms of risk estimation (CT vs CC; p<0.05, OR=1.53, 95% CI=1.03-2.28, CT+TT vs CC; p<0.001, OR=1.922, 95% CI=1.31-2.82). Remaining loci demonstrated no significance with risk. Of the 21 loci screened, RAD52 2259 and RAD52 GLN221GLU may be of importance to disease process and may be associated with papillary thyroid cancer risk in Saudi Arabian population.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19092295     DOI: 10.1007/BF03346438

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  28 in total

1.  Incidence of thyroid cancer in Scandinavia following fallout from atomic bomb testing: an analysis of birth cohorts.

Authors:  E Lund; M R Galanti
Journal:  Cancer Causes Control       Date:  1999-06       Impact factor: 2.506

2.  Rapid assessment of repair of ultraviolet DNA damage with a modified host-cell reactivation assay using a luciferase reporter gene and correlation with polymorphisms of DNA repair genes in normal human lymphocytes.

Authors:  Yawei Qiao; Margaret R Spitz; Zhaozheng Guo; Mohammad Hadeyati; Lawrence Grossman; Kenneth H Kraemer; Qingyi Wei
Journal:  Mutat Res       Date:  2002-11-30       Impact factor: 2.433

3.  No association between a stop codon polymorphism in RAD52 and breast cancer risk.

Authors:  Jiali Han; Susan E Hankinson; Immaculata De Vivo; Graham A Colditz; David J Hunter
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2002-10       Impact factor: 4.254

4.  Polymorphisms in exon 13 and intron 14 of the RET protooncogene: genetic modifiers of medullary thyroid carcinoma?

Authors:  S M Baumgartner-Parzer; R Lang; L Wagner; G Heinze; B Niederle; K Kaserer; W Waldhäusl; H Vierhapper
Journal:  J Clin Endocrinol Metab       Date:  2005-08-23       Impact factor: 5.958

5.  DNA repair gene polymorphisms, bulky DNA adducts in white blood cells and bladder cancer in a case-control study.

Authors:  G Matullo; S Guarrera; S Carturan; M Peluso; C Malaveille; L Davico; A Piazza; P Vineis
Journal:  Int J Cancer       Date:  2001-05-15       Impact factor: 7.396

6.  Polymorphisms in the initiators of RET (rearranged during transfection) signaling pathway and susceptibility to sporadic medullary thyroid carcinoma.

Authors:  Arancha Cebrian; Fabienne Lesueur; Sam Martin; Jean Leyland; Shahana Ahmed; Craig Luccarini; Paula L Smith; Robert Luben; Joanne Whittaker; Paul D Pharoah; Alison M Dunning; Bruce A J Ponder
Journal:  J Clin Endocrinol Metab       Date:  2005-08-09       Impact factor: 5.958

7.  Cancer statistics, 2005.

Authors:  Ahmedin Jemal; Taylor Murray; Elizabeth Ward; Alicia Samuels; Ram C Tiwari; Asma Ghafoor; Eric J Feuer; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2005 Jan-Feb       Impact factor: 508.702

8.  Irradiation and second cancers. The thyroid as a case in point.

Authors:  M Schlumberger; A F Cailleux; H G Suarez; F de Vathaire
Journal:  C R Acad Sci III       Date:  1999 Feb-Mar

Review 9.  DNA double strand break repair in mammalian cells.

Authors:  P Karran
Journal:  Curr Opin Genet Dev       Date:  2000-04       Impact factor: 5.578

10.  A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns].

Authors:  S A Hundahl; I D Fleming; A M Fremgen; H R Menck
Journal:  Cancer       Date:  1998-12-15       Impact factor: 6.860

View more
  27 in total

1.  Association between TP53 Arg72Pro polymorphism and thyroid carcinoma risk.

Authors:  Fang Wang; Peng Wang; Bin Wang; Zheng-Ju Fu; Ying Yuan; Sheng-Li Yan; Wen-Juan Zhao; Yan-Gang Wang
Journal:  Tumour Biol       Date:  2013-12-28

2.  Association between p53 Arg72Pro polymorphism and thyroid cancer risk: a meta-analysis.

Authors:  Bo Wu; Dan Guo; Ying Guo
Journal:  Tumour Biol       Date:  2013-09-15

3.  Common genetic variants related to genomic integrity and risk of papillary thyroid cancer.

Authors:  Gila Neta; Alina V Brenner; Erich M Sturgis; Ruth M Pfeiffer; Amy A Hutchinson; Briseis Aschebrook-Kilfoy; Meredith Yeager; Li Xu; William Wheeler; Michael Abend; Elaine Ron; Margaret A Tucker; Stephen J Chanock; Alice J Sigurdson
Journal:  Carcinogenesis       Date:  2011-06-03       Impact factor: 4.944

4.  Evaluation of miRNA-binding-site SNPs of MRE11A, NBS1, RAD51 and RAD52 involved in HRR pathway genes and risk of breast cancer in China.

Authors:  Zhenzhen Wu; Peng Wang; Chunhua Song; Kaijuan Wang; Rui Yan; Jingruo Li; Liping Dai
Journal:  Mol Genet Genomics       Date:  2015-01-09       Impact factor: 3.291

5.  Current evidence on the relationship between three polymorphisms in the XRCC7 gene and cancer risk.

Authors:  Jian Zhang; Xiang-Hua Wu; Yu Gan
Journal:  Mol Biol Rep       Date:  2012-10-30       Impact factor: 2.316

6.  DNA double-strand break repair gene XRCC7 genotypes were associated with hepatocellular carcinoma risk in Taiwanese males and alcohol drinkers.

Authors:  Yi-Hsien Hsieh; Wen-Shin Chang; Chia-Wen Tsai; Jen-Pi Tsai; Chin-Mu Hsu; Long-Bin Jeng; Da-Tian Bau
Journal:  Tumour Biol       Date:  2015-05-06

7.  No association between XRCC1 genetic polymorphisms and differentiated thyroid carcinoma risk: a meta-analysis.

Authors:  Cuiping Li; Xue Xiang; Yang Zhou
Journal:  Mol Biol Rep       Date:  2014-08-03       Impact factor: 2.316

8.  A RAD52 genetic variant located in a miRNA binding site is associated with glioma risk in Han Chinese.

Authors:  Chao Lu; Yi-Dong Chen; Sichong Han; Jinyu Wei; Yunxia Ge; Wenting Pan; Tao Jiang; Xiao-Guang Qiu; Ming Yang
Journal:  J Neurooncol       Date:  2014-07-11       Impact factor: 4.130

9.  Association of XRCC1 polymorphisms with thyroid cancer risk.

Authors:  Cong Wang; Zhilong Ai
Journal:  Tumour Biol       Date:  2014-01-30

10.  Association between x-ray repair cross-complementing group 3 (XRCC3) genetic polymorphisms and papillary thyroid cancer susceptibility in a Chinese Han population.

Authors:  Kai Yuan; Meiling Huo; Yong Sun; Hongyan Wu; Hongqiang Chen; Yulong Wang; Rongzhan Fu
Journal:  Tumour Biol       Date:  2015-08-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.